Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space
Executive Summary
AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.
You may also be interested in...
Oncology Market Leaders Maintain Their Upper Hand
Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.
Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.